Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
PET/CT scans allow you to see inside your bone marrow. Multiple myeloma is a cancer of the plasma cells. Plasma cells that multiply uncontrollably in a person’s bone marrow. In order to
the patient’s plasma cells, you need to see inside a person’s bone marrow. This is a challenge to say the least.
Positron emission tomography/computed tomography (PET/CT) scans play a valuable role in the management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key aspects of the value of PET/CT scans in multiple myeloma:
“Multiple Myeloma (MM) is a plasma cell malignancy characterized by diverse clinical presentations. While biochemical assessment of disease activity is commonly utilized to monitor treatment response, findings on magnetic resonance imaging and positron emission tomography/computed tomography (PET/CT), among other imaging modalities, have proven to harbor prognostic value.
We sought to corroborate these findings by examining the prognostic significance of Fluorodeoxyglucose (FDG) PET/CT scanning in the setting of newly diagnosed MM.
We retrospectively analyzed 195 patients with a PET/CT available both
to examine the value of PET/CT results as an adjuvant metric to conventional hematologic responses in terms of time to next treatment (TTNT) and overall survival (OS).
The median TTNT and OS for the entire cohort were 24.6 and 79 months, respectively.
When comparing PET/CT (-) with PET/CT (+) patients, we found significantly prolonged median TTNT (55.2 vs. 17.8 months, p<0.0001) and OS (unreached vs. 60.8 months, p<0.0001) for the PET/CT (-) group.
We then examined the additive value of PET/CT on the hematologic response achieved at 6 months, and we found that PET/CT (-) is associated with significantly increased median TTNT and OS for both the very good partial response (VGPR) group and the less than VGPR group.
Importantly, PET/CT retained prognostic significance after adjusting for multiple other predictive variables.
We conclude that a PET/CT (-) at 6 months confers a significant prognostic advantage for newly diagnosed MM patients and adds significant value to the hematologic response assessment.”